To assess the incidence of venous thromboembolism (VTE) events by mode of incision among hysterectomies and myomectomies. MATERIALS AND METHODS: This was a retrospective study at Beth Israel Deaconess Medical Center, an academic tertiary-care center. All women who underwent hysterectomy or myomectomy from May 2006 to April 2014 were included. The mode of incision along with other patient and surgical characteristics were reviewed. The incidence of VTE was analyzed by mode of incision and type of surgery. RESULTS: There were 3409 hysterectomies (269 cancer, 3140 benign) and 1006 myomectomies (2 malignancies). The breakdown by mode of incision was: 1761 (54.7%) abdominal hysterectomies (AH), 860 (25.2%) laparoscopic hysterectomies (LH), 312 (9.2%) robotic hysterectomies (RH), 244 (7.2%) laparoscopically assisted vaginal hysterectomies (LAVH), and 232 (6.8%) vaginal hysterectomies (VH); 503 (50%) abdominal myomectomies (AM), 79 (7.9%) laparoscopic myomectomies (LM), 48 (4.8%) robotic myomectomies (RM), and 376 (37.3%) vaginal/hysteroscopic myomectomies (VM). The incidence of VTE was 1.2% for all hysterectomies. Among the different modes of hysterectomy, laparotomies had the highest VTE incidence (AH ¼ 1.9%) followed by LHs (0.6%) and RHs (0.6%). There were no VTEs among LAVHs or VHs. Patients with cancer with AHs had the greatest risk of VTE (3.9%) among all patients. There were no VTEs among cancer patients who underwent a minimally invasive hysterectomy with 0% VTE incidence among LH, RH, LAVH, and VHs. Myomectomies had a very low VTE incidence (0.2%) with only 2 VTEs total. See Table 1 . Two-thirds of all patients received mechanical VTE prophylaxis (e.g. pneumoboots) and 1/3 received pharmacologic prophylaxis (e.g. subcutaneous heparin). Among the VTE patients, the majority received pharmacologic (79.1%) and mechanical (67.4%) prophylaxis. There were more cancers diagnosed among VTE patients (16.3%) compared to the non-VTE patients (6.1%) with a higher VTE incidence among patients with cancer (2.6%) compared to non-cancer patients (0.87%). The median length of surgery was 22 minutes longer for VTE patients compared to non-VTE patients. CONCLUSION: Current CHEST guidelines suggest the same VTE prophylaxis should be applied to major gynecologic surgeries regardless of abdominal versus laparoscopic approach. However, our results suggest the incidence of VTE among hysterectomies and myomectomies differ by mode of incision, with a much lower incidence among minimally invasive modes of surgery.
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OBJECTIVES:
Rectovaginal fistula (RVF) may occur as complication of malignancy, obstetric trauma, radiation, inflammatory bowel disease, infection and/or surgery. Flaps may be used in fistula repair to aid healing in complex cases refractory to standard techniques. The purpose of this study was to investigate outcomes of flap reconstruction of RVF. MATERIALS AND METHODS: All patients who underwent flap reconstruction of any type of fistula at Mayo Clinic between January 1995 and December 2014 were identified using electronic medical records for this retrospective cohort study. All men were excluded. Women undergoing RVF repair using flap reconstruction were then identified and baseline demographics including surgical indications were obtained. Surgical outcomes and complications were collected by chart review. Operative success was defined as absence of fistula recurrence within six months of surgery. RESULTS: A total of 59 patients were identified as having undergone flap reconstructions for management of a fistula. Of these, 42 (71.2%) were women and, specifically 31 had a flap used in the treatment of a rectovaginal fistula. Rectovaginal fistula etiologies included 10 (32.3%) with malignancy, 7 (22.6%) with Crohn's disease or ulcerative colitis, 6 (19.4%) with obstetric complications, 3 (9.7%) with diverticulitis or infection, and 5 (16.1%) other. There were 35 flap reconstructions performed on this cohort of 31 women. A total of 20 (57.1%) had prior fistula repair attempt before flap reconstruction. Of the 35 flaps used, 13 (37.2%) were Martius, 11 (31.4%) were gracilis, and 11 (31.4%) were other (omental, psoas, mucosal, and rectus abdominis). Overall, 19 (54.3%) had successful repair, while 16 (45.7%) experienced recurrent fistula. Of the 10 who had preoperative radiation, 7 (70%) had successful repair. Of the 10 who had malignancy, 7 (70%) had successful repair. Of the 7 who had inflammatory bowel disease, 5 (71.4%) had successful repair. Three (50.0%) of the 6 patients who had obstetric etiology had successful repair; however one of these patients experienced a flap failure followed by flap repair success resulting in an overall success rate of 42.9% in patients with obstetric etiology. All patients with obstetric etiology had experienced at least one failed repair prior to flap placement. CONCLUSION: Flap use in repair of RVF is a viable option, particularly in complex cases. Approximately 70% of patients who had preoperative radiation, malignancy, or bowel disease had successful flap reconstruction of RVF. Flap reconstruction was less successful in women with a complicated fistula of obstetric etiology.
